Tech Company Inital Public Offerings

Stoke Therapeutics IPO

On 6/18/2019, Stoke Therapeutics became a public company.

Transaction Overview

Company Name
Announced On
6/18/2019
Transaction Type
IPO
Amount
$142,000,000
Proceeds Purpose
Per the firm's latest filing, it plans to use the net proceeds from the IPO as follows: approximately $36.0 million to $39.0 million to advance our lead product candidate, STK-001, through initiation of a Phase 3 clinical trial; approximately $34.0 million to $37.0 million to nominate, conduct preclinical studies for and demonstrate clinical proof of concept for additional product candidates; and any remaining amounts to fund working capital and general corporate purposes.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3 Preston Ct. 102
Bedford, MA 01730
USA
Email Address
Overview
Stoke (Nasdaq: STOK) is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
Profile
Stoke Therapeutics LinkedIn Company Profile
Social Media
Stoke Therapeutics Company Twitter Account
Company News
Stoke Therapeutics News
Facebook
Stoke Therapeutics on Facebook
YouTube
Stoke Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Edward Kaye
  Edward Kaye LinkedIn Profile  Edward Kaye Twitter Account  Edward Kaye News  Edward Kaye on Facebook
Chief Medical Officer
Barry Ticho
  Barry Ticho LinkedIn Profile  Barry Ticho Twitter Account  Barry Ticho News  Barry Ticho on Facebook
Chief Operating Officer
Huw Nash
  Huw Nash LinkedIn Profile  Huw Nash Twitter Account  Huw Nash News  Huw Nash on Facebook
Vice President
Charles Allerson
  Charles Allerson LinkedIn Profile  Charles Allerson Twitter Account  Charles Allerson News  Charles Allerson on Facebook
Vice President
Isabel Aznarez
  Isabel Aznarez LinkedIn Profile  Isabel Aznarez Twitter Account  Isabel Aznarez News  Isabel Aznarez on Facebook
VP - R & D
Gene Liau
  Gene Liau LinkedIn Profile  Gene Liau Twitter Account  Gene Liau News  Gene Liau on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/18/2019: IronScales venture capital transaction
Next: 6/18/2019: Quartet venture capital transaction

 

Share this article

 


Where The Data Comes From

We document all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary